Skip to main content

My-O-Den Side Effects

Generic name: adenosine

Medically reviewed by Last updated on May 27, 2023.

Note: This document contains side effect information about adenosine. Some dosage forms listed on this page may not apply to the brand name My-O-Den.

Applies to adenosine: intravenous solution.

Serious side effects of My-O-Den

Along with its needed effects, adenosine (the active ingredient contained in My-O-Den) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking adenosine:

More common

Less common


Other side effects of My-O-Den

Some side effects of adenosine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common


For Healthcare Professionals

Applies to adenosine: compounding powder, intravenous solution, sublingual spray.


The most common adverse reactions are flushing, chest discomfort, dyspnea, facial flushing, headache, throat/neck/jaw discomfort, gastrointestinal discomfort, and lightheadedness/dizziness.[Ref]


Very common (10% or more): Flushing (44%), facial flushing (18%)

Common (1% to 10%): First degree atrioventricular block, second degree atrioventricular block, hypotension, arrhythmias, ventricular tachycardia

Uncommon (0.1% to 1%): Bradycardia, sinus tachycardia, palpitations

Very rare (less than 0.01%): Atrial fibrillation, ventricular fibrillation, Torsade de pointes, severe bradycardia

Frequency not reported: Myocardial infarction, ventricular arrhythmia, third degree atrioventricular block, sinus exit block, sinus pause, hypertension, skipped beats, atrial extrasystoles, ventricular extrasystoles

Postmarketing reports: Cardiac arrest/asystole, cardiac failure, tachycardia, prolonged asystole, transient increase in blood pressure[Ref]


Very common (10% or more): Chest discomfort (40%)

Common (1% to 10%): ST segment depression, chest pressure

Uncommon (0.1% to 1%): Feeling of general discomfort/weakness/pain

Rare (less than 0.1%): Tinnitus, nipple discomfort

Frequency not reported: Chest pain, feeling of thoracic constriction/oppression, weakness, T wave changes, ear discomfort, tongue discomfort, heaviness in arms, pressure in groin

Postmarketing reports: ST segment elevation[Ref]


Very common (10% or more): Dyspnea (up to 28%)

Uncommon (0.1% to 1%): Hyperventilation

Rare (0.01% to 0.1%): Bronchospasm, nasal congestion

Very rare (less than 0.01%): Respiratory failure

Frequency not reported: Cough, throat tightness

Postmarketing reports: Respiratory arrest/apnea[Ref]

Nervous system

Very common (10% or more): Headache (up to 18%), lightheadedness/dizziness (12%)

Common (1% to 10%): Paresthesia, tingling in arms, numbness, burning sensation

Uncommon (0.1% to 1%): Metallic taste, head pressure

Rare (0.01% to 0.1%): Tremor, drowsiness

Very rare (less than 0.01%): Intracranial hypertension worsening

Frequency not reported: Scotomas, convulsions

Postmarketing reports: Cerebrovascular accident, intracranial hemorrhage, seizure, tonic clonic seizures, loss of consciousness/syncope[Ref]


Very common (10% or more): Throat/neck/jaw discomfort (15%)

Common (1% to 10%): Upper extremity discomfort

Frequency not reported: Back discomfort, lower extremity discomfort, neck and back pain[Ref]


Very common (10% or more): Gastrointestinal discomfort (13%)

Common (1% to 10%): Dry mouth, nausea

Frequency not reported: Abdominal discomfort

Postmarketing reports: Vomiting[Ref]


Common (1% to 10%): Nervousness, apprehension

Frequency not reported: Emotional instability[Ref]


Uncommon (0.1% to 1%): Sweating

Postmarketing reports: Angioedema, urticaria, rash[Ref]


Uncommon (0.1% to 1%): Blurred vision[Ref]


Rare (less than 0.1%): Urinary urgency

Frequency not reported: Vaginal pressure[Ref]


Very rare (less than 0.01%): Injection site reaction

Postmarketing reports: Infusion site pain[Ref]


Postmarketing reports: Hypersensitivity, anaphylaxis[Ref]


1. Product Information. Prograf (tacrolimus). Fujisawa. 2001;PROD.

2. Cerner Multum, Inc. UK Summary of Product Characteristics.

3. Cerner Multum, Inc. Australian Product Information.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.